Neurogene Inc.

NASDAQ: NGNE
Share price (1/3/25): $23.23
Market cap (1/3/25): $345 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 09/30/24 Q3

Late quarterly filing notification for Q3 2024

ended 06/30/24 Q2

ended 03/31/24 Q1

ended 12/31/23 FY 2023

Prospectuses and Registrations Filter

Prospectus supplement

Initial registration of new securities

Registration of securities for employees

Business combination disclosure

Business combination disclosure

Ownership Filter

Commodore Capital LP

Akkaraju Srinivas, Samsara BioCapital, L.P., Samsara BioCapital GP, LLC

Akkaraju Srinivas, Samsara BioCapital, L.P., Samsara BioCapital GP, LLC

Samsara BioCapital, L.P.

Cvijic Christine Mikail

News Filter

Material Disclosure

Reports Third Quarter 2024 Financial Results and Highlights Recent Updates

Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Reports Positive Interim Efficacy Data From First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Announces Oversubscribed $200 Million Private Placement

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Preliminary proxy

Other Filter

Notice of effectiveness

Scanned paper annual report submission

SEC STAFF LETTER

Notice of effectiveness

Correspondence with the SEC